Decipher is consistent across trials in IDing group benefiting from intensification. @ChrisSweens1 presents data from ENZAMET - great collab btw @Decipher_VCYT@ANZUPtrials and participating centers. More molecular data coming from ENZAMET - see our germline profiling poster tmrw
Personalized intensification of treatment for hormone-sensitive prostate cancer
nature.com/articles/s41571-0…
Hormone-sensitive #ProstateCancer (HSPC) management has advanced beyond androgen-deprivation therapy (ADT) alone, now incorporating androgen receptor pathway inhibitors (ARPIs), docetaxel, and radiotherapy based on disease state and biology.
Modern PSMA PET imaging detects metastases earlier than conventional scans, redefining patient subgroups and influencing decisions such as when to use chemotherapy or radiotherapy. Treatment is increasingly personalized, guided by prior local therapy, PSA dynamics, disease volume, and imaging findings, with ARPI–ADT doublets forming the backbone for metastatic disease. Attention to toxicity from long-term testosterone suppression is crucial, while emerging biomarker-driven therapies—including ^177Lu-PSMA-617, AKT inhibitors, and PARP inhibitors—are poised to further refine care.
@drcilento@LisaButler5@drlouiseemmett@ChrisSweens1@OncoAlert 🚨
@Silke_Gillessen@AOmlin@weoncologists
The second #ProstateCancer session at #UromigosLive 2025 was a discussion about the approach to mHSPC, building on ADT+ARPI and debating the inclusion of a third agent including docetaxel, PARPi, radioligand or AKT inhibition. Uromigos.org for full videos with slides. @OncoAlert
Immune checkpoint inhibitors can improve survival in solid organ transplant recipients with advanced cancers, but survival rates remain limited.
#TSANZConf@TSANZ_txsocja.ma/43Rsa7C
Stunning research from @EdmondMKwan on ctDNA in theranostics:
🧬Low ctDNA predicts better response with ¹⁷⁷Lu-PSMA-617 vs. cabazitaxel chemotherapy
⚠️PTEN alterations linked to worse outcomes on cabazitaxel
🧪ATM defects tied to favorable PSMA-617 results
🩻PET quantitative biomarkers (SUVmean) are additive
🌟We identify new candidate biomarkers for ¹⁷⁷Lu–PSMA-617 selection and ultimately expand the mCRPC predictive biomarker repertoire
Online at @NatureMedicinenature.com/articles/s41591-0…@ANZUPtrials#TheraP@MovemberAUS@PCFA
Support by @PCF_Science Challenge Award
@ResearchWyatt@AzadOncology@Prof_IanD